1.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3066K1-3311, NCT00631371
|
|
2.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MAYO-MC0452, NCI-6986, 6986, NCT00112840
|
|
3.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-N0572, N0572, NCT00329719
|
|
4.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ABTC-05-02, NABTC-05-02, NCT00335764
|
|
5.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MDA-2005-0215, 7149, NCI-7149, NCT00349206
|
|
6.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 06-365, NCT00483262
|
|
7.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MAYO-MC0736, 8129, MC0736, NCT00699491
|
|
8.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-N078D, N078D, NCT00787969
|
|
9.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2008-0827, NCT00877773
|
|
10.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E2804, E2804, NCT00378703
|
|
11.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: UVACC-MEL-47, Mel 47, 7190, NCI-7190, NCT00397982
|
|
12.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: TORAVA, ET2007-035, NCT00619268
|
|
13.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: NCI
Protocol IDs: GOG-0248, GOG-0248, NCT00729586
|
|
14.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: GIMEMA-AML-1107, GIMEMA AML1107, EUDRACT-2007-005374-31, EU-20886, WYETH-GIMEMA-AML-1107, NCT00775593
|
|
15.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 08-184, NCT00782275
|
|
16.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BEV-CCI-779-GBM-02, Eudract no.: 2008-003679-40, NCT00800917
|
|
17.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 18
Sponsor: Other
Protocol IDs: NB2008, NCT00808899
|
|
18.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: 2008-007665-22, NCT00827684
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 201170, NCT00838955
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: 00016256, NCT00887640
|
|
21.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: NCI
Protocol IDs: UCIRVINE-UCI-04-04, 6619, NCI-6619, NCT00101088
|
|
22.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: FCCC-04037, 5785, NCI-5785, NCT00112476
|
|
23.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-N027D, N027D, NCT00316849
|
|
24.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: OSU-05115, 7314, OSU-2006C0040, NCT00398515
|
|
25.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UCIRB 15424A, NCT00523432
|
